Kera Capital Partners Inc. Makes New $3.79 Million Investment in Medline $MDLN

Kera Capital Partners Inc. bought a new stake in shares of Medline (NASDAQ:MDLN) during the 4th quarter, Holdings Channel.com reports. The fund bought 85,642 shares of the company’s stock, valued at approximately $3,785,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sound Income Strategies LLC purchased a new stake in shares of Medline during the 4th quarter worth $25,000. Entrust Financial LLC purchased a new position in Medline in the fourth quarter valued at about $26,000. NBC Securities Inc. purchased a new position in Medline in the fourth quarter valued at about $28,000. Global Retirement Partners LLC bought a new position in Medline in the fourth quarter worth about $31,000. Finally, North Star Investment Management Corp. purchased a new stake in shares of Medline during the fourth quarter valued at about $36,000.

Medline Stock Down 1.3%

Shares of Medline stock opened at $35.94 on Friday. The firm has a 50 day moving average of $40.19. The stock has a market cap of $47.21 billion and a price-to-earnings ratio of 112.31. The company has a quick ratio of 2.51, a current ratio of 4.41 and a debt-to-equity ratio of 0.65. Medline has a 52 week low of $32.81 and a 52 week high of $50.88.

Medline (NASDAQ:MDLN) last released its earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.04. The company had revenue of $7.35 billion for the quarter. The company’s quarterly revenue was up 10.7% on a year-over-year basis. As a group, research analysts anticipate that Medline will post 1.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MDLN. Barclays lowered their price target on shares of Medline from $50.00 to $45.00 and set an “overweight” rating on the stock in a report on Monday, June 1st. Morgan Stanley increased their target price on shares of Medline from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Monday, March 2nd. BMO Capital Markets raised their target price on shares of Medline from $45.00 to $54.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Sanford C. Bernstein cut their price target on shares of Medline from $56.00 to $54.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Royal Bank Of Canada upped their price target on Medline from $47.00 to $53.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $50.54.

Insider Buying and Selling at Medline

In other news, insider Douglas P. Golwas sold 100,000 shares of Medline stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $36.77, for a total transaction of $3,677,000.00. Following the completion of the sale, the insider directly owned 23,899 shares in the company, valued at approximately $878,766.23. The trade was a 80.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jessi L. Corcoran acquired 5,000 shares of Medline stock in a transaction dated Friday, June 5th. The stock was purchased at an average price of $34.15 per share, with a total value of $170,750.00. Following the completion of the purchase, the insider owned 5,000 shares of the company’s stock, valued at approximately $170,750. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 0.81% of the company’s stock.

Medline Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.